Intech Investment Management LLC Sells 106,311 Shares of Pfizer Inc. $PFE

Key Points

• Intech Investment Management LLC reduced its stake in Pfizer Inc. by 26.1% in Q1, selling 106,311 shares, leaving it with 300,792 shares valued at $7.62 million.
• Despite the reduction from Intech, several other large investors have increased their holdings in Pfizer during the same quarter, indicating overall institutional confidence in the company.
• Pfizer recently reported better-than-expected earnings, with $0.78 EPS, surpassing analyst estimates of $0.58, and announced a quarterly dividend of $0.43, equating to an annual yield of 6.9%.

Intech Investment Management LLC cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 26.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 300,792 shares of the biopharmaceutical company's stock after selling 106,311 shares during the period. Intech Investment Management LLC's holdings in Pfizer were worth $7,622,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of PFE. William B. Walkup & Associates Inc. raised its stake in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after purchasing an additional 454 shares in the last quarter. Members Trust Co raised its position in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 467 shares in the last quarter. Sutton Place Investors LLC raised its position in shares of Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after buying an additional 472 shares in the last quarter. MSH Capital Advisors LLC boosted its position in shares of Pfizer by 1.4% during the 1st quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after acquiring an additional 485 shares in the last quarter. Finally, Signature Estate & Investment Advisors LLC increased its stake in Pfizer by 2.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company's stock valued at $488,000 after acquiring an additional 486 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Stock Performance

Pfizer stock opened at $24.84 on Friday. The business has a 50 day moving average of $24.82 and a 200-day moving average of $24.32. The company has a market capitalization of $141.23 billion, a P/E ratio of 13.21, a P/E/G ratio of 0.87 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.